Eganelisib

DRUG2 trials

Sponsors

Stelexis BioSciences, Jacqueline Garcia, MD

Conditions

AML, AdultAcute Myeloid LeukemiaLeukemiaLeukemia, MyeloidMDSRefractory Leukemia

Phase 1

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

RecruitingNCT06533761

Stelexis BioSciencesAML, Adult, MDS

Start: 2025-04-28End: 2028-03-15Target: 125Updated: 2026-08-25

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

RecruitingNCT07439211

Jacqueline Garcia, MDAcute Myeloid Leukemia, Leukemia, Leukemia, Myeloid +1

Start: 2026-04-13End: 2029-02-01Target: 48Updated: 2026-08-26

Related Papers

Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML).

Journal of Clinical Oncology2026-05-27

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib As Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood2024-11-05